Finance Watch: Tetraphase Reorganization Follows Troubled Antibiotic Commercialization Path
Executive Summary
Tetraphase's plan to downsize may put the company on the same path as now-bankrupt Achaogen. Also, Bain raises $900m for its second life science fund, Provention calls off post-ADA offering and Oncologie raises $80m series B.
You may also be interested in...
Can Basilea’s Antibiotic Succeed Where Others Have Failed?
The Swiss biotech says the ERADICATE trial shows areas of differentiation for the antibiotic, like utility in pneumonia and across gram-negative and gram-positive bacteria.
Nabriva Hopes To Relaunch Xenleta In Community Setting As Pandemic Subsides
Moving away from its earlier hospital-based focus with the novel antibiotic, Nabriva also thinks selling Merck & Co.’s Sivextro will provide complementary business.
Antibiotic Action Fund Remains Stop-Gap As Industry Waits For Reimbursement Legislation
Pharma-backed investment fund to combat antimicrobial resistance aims to find Phase II-ready programs, but can’t generate a constant flow of innovation without better ‘pull’ incentives, industry says.